Get notified when RKTO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Auditor expressed substantial doubt about the company's ability to continue as a going concern for the year ended December 31, 2025 due to recurring losses and negative cash flows.
- Material Weakness (removed) — Material weakness in classification of prepaid expenses and R&D costs disclosed in 2024 filing is no longer present in 2025 filing; controls now deemed effective.
Hoth Therapeutics reports 52% loss increase, auditor raises going-concern doubt
Filed March 27, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 28, 2025 · ~2 min read
Key Changes
-
high
Net loss jumped 52% to $12.5M (2025) from $8.2M (2024); cash fell to $6.2M; company now states existing cash insufficient for 12 months, reversing prior adequacy statement. Auditor expressed substantial doubt about ability to continue as going concern.
MD&A: Liquidity / Notes: Going Concern verify on EDGAR → -
high
Material weakness in internal controls over R&D expense classification remediated; disclosure controls and internal controls now deemed effective as of December 31, 2025, reversing prior-year ineffective conclusion.
Controls & Procedures verify on EDGAR → -
high
HT-001 Phase 2a trial expanded to Europe (Spain, Poland, Hungary) after EMA approval in January 2026; company also initiated proof-of-concept studies for three new HT-001 indications, broadening addressable market.
Business: HT-001 Development verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade RKTO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 3, 2026 9:58 PM